StoxAjanta Pharmaceuticals vs Global Health: share price & financials comparison
NSE: AJANTPHARM vs MEDANTA · Healthcare · as of 06 Nov 2026
Both prices rebased to 100 at the start of the selected period.
Ajanta Pharmaceuticals vs Global Health at a glance
Ajanta Pharmaceuticals (AJANTPHARM) has a market capitalisation of ₹41,462 Cr, against ₹37,281 Cr for Global Health (MEDANTA). Over the past year Ajanta Pharmaceuticals has returned +34.4%, compared with +0.9% for Global Health. On valuation, Ajanta Pharmaceuticals trades at a lower P/E of 32.9 versus 93.7. Ajanta Pharmaceuticals earns a higher return on equity (25.9% vs 9.2%). Ajanta Pharmaceuticals comes out ahead on size, valuation, profitability and financial health. Global Health comes out ahead on growth and technicals. Across the scored metrics below, Ajanta Pharmaceuticals leads on 11 and Global Health on 5. On StoxGud's 10-point checklist, Ajanta Pharmaceuticals scores 9/10 and Global Health scores 6/10.
| Metric | Ajanta Pharmaceuticals | Global Health |
|---|---|---|
| Size | ||
| Market cap | ₹41,462 Cr | ₹37,281 Cr |
| Revenue (latest FY) | ₹5,453 Cr | ₹4,410 Cr |
| Net profit (latest FY) | ₹1,056 Cr | ₹556 Cr |
| Valuation | ||
| P/E | 32.9 | 93.7 |
| P/B | 8.53 | 8.62 |
| Dividend yield | 0.84% | 0.04% |
| Profitability | ||
| Return on equity | 25.9% | 9.2% |
| Net profit margin | 20.2% | 7.9% |
| Operating margin | 27.1% | 22.1% |
| Growth | ||
| Revenue growth (YoY) | +32.5% | +33.6% |
| Net profit growth (YoY) | +49.2% | -100.0% |
| Revenue CAGR (multi-year) | +13.5% | +17.9% |
| Financial health | ||
| Debt to equity | 0.02 | 0.16 |
| Momentum | ||
| 1-month return | -7.3% | +7.2% |
| 1-year return | +34.4% | +0.9% |
| 3-year CAGR | +22.1% | +18.3% |
| 5-year CAGR | +17.9% | — |
| 10-year CAGR | +10.0% | — |
| Distance from 52W high | -11.0% | -8.0% |
| Technicals | ||
| RSI (14) | 48 | 71 |
| Price vs 200-day avg | +4.1% | +11.1% |
Highlighted cells lead on that metric. Market cap, revenue and RSI are shown for context and not scored.
10-point checklist side by side
| Check | Ajanta Pharmaceuticals | Global Health |
|---|---|---|
| Price above 50-day average | ✗ | ✓ |
| Price above 200-day average | ✓ | ✓ |
| 50-day average above 200-day (uptrend) | ✓ | ✓ |
| RSI in healthy 40–70 zone | ✓ | ✗ |
| Positive 1-year return | ✓ | ✓ |
| Return on equity above 15% | ✓ | ✗ |
| Debt to equity below 1 | ✓ | ✓ |
| Revenue growing year on year | ✓ | ✓ |
| Net profit margin above 10% | ✓ | ✗ |
| P/E below industry median | ✓ | ✗ |
| Score | 9/10 | 6/10 |
A rules-based screen for education only — not a buy or sell recommendation.
FAQs
Which is bigger, Ajanta Pharmaceuticals or Global Health?
Ajanta Pharmaceuticals has a market cap of ₹41,462 Cr and Global Health has a market cap of ₹37,281 Cr as of 06 Nov 2026.
Which has a lower P/E, Ajanta Pharmaceuticals or Global Health?
Ajanta Pharmaceuticals has the lower P/E: Ajanta Pharmaceuticals trades at 32.9 and Global Health at 93.7.
Which gave better returns in the last year, Ajanta Pharmaceuticals or Global Health?
Ajanta Pharmaceuticals did better: Ajanta Pharmaceuticals returned +34.4% and Global Health returned +0.9% over one year.
Is Ajanta Pharmaceuticals or Global Health a better buy?
StoxGud does not give buy or sell recommendations. On our rules-based checklist Ajanta Pharmaceuticals scores 9/10 and Global Health scores 6/10; compare valuation, profitability, growth and momentum above and consult a SEBI-registered adviser.